Sign Up For Our Newsletter
Weekly insights into the future of longevity
Longevity investors from around the world are now funneling in billions of dollars each year in pursuit of extended human healthspan and lifespan. With a global aging population fueling this growing trend, interest in human health combined with advances in biotech are only positioned to accelerate further.
Spannr has aggregated extensive financial data across public, private, non-profit, and crypto markets to bring context to investing trends within longevity. More data about specific investors and companies is available upon request.
GV | 81 |
---|---|
ARCH Venture Partners | 52 |
Casdin Capital | 49 |
Polaris Partners | 39 |
Alexandria Venture Investments | 38 |
Khosla Ventures | 38 |
Perceptive Advisors | 32 |
Foresite Capital | 26 |
National Institutes of Health (NIH) | 25 |
OrbiMed | 25 |
Alnylam Pharmaceuticals | $4,686,000,000 |
---|---|
BICO Group AB | $3,602,746,320 |
Altos Labs | $3,000,000,000 |
Invitae | $2,070,800,000 |
Resilience | $1,975,000,000 |
Grail | $1,690,000,000 |
Relay Therapeutics | $1,630,000,000 |
Sana Biotechnology | $1,375,600,000 |
Intellia Therapeutics | $1,353,900,000 |
Blueprint Medicines | $1,286,400,000 |